SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-012227
Filing Date
2024-08-14
Accepted
2024-08-14 16:05:57
Documents
63
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q anvs-20240630x10q.htm   iXBRL 10-Q 1105285
2 EX-31.1 anvs-20240630xex31d1.htm EX-31.1 12909
3 EX-32.1 anvs-20240630xex32d1.htm EX-32.1 5561
  Complete submission text file 0001558370-24-012227.txt   5340271

Data Files

Seq Description Document Type Size
4 EX-101.SCH anvs-20240630.xsd EX-101.SCH 39637
5 EX-101.CAL anvs-20240630_cal.xml EX-101.CAL 30443
6 EX-101.DEF anvs-20240630_def.xml EX-101.DEF 144529
7 EX-101.LAB anvs-20240630_lab.xml EX-101.LAB 320387
8 EX-101.PRE anvs-20240630_pre.xml EX-101.PRE 258563
66 EXTRACTED XBRL INSTANCE DOCUMENT anvs-20240630x10q_htm.xml XML 923742
Mailing Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355
Business Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 484-875-3192
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

IRS No.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39202 | Film No.: 241207546
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)